Lower Extremity Revascularization in End-Stage Renal Disease
- PMID: 27770080
- DOI: 10.1177/1538574416674843
Lower Extremity Revascularization in End-Stage Renal Disease
Abstract
Patients with end-stage renal disease (ESRD) who present with critical limb ischemia (CLI) have become an increasingly common and complex treatment problem for vascular surgeons. Dialysis patients have high short-term mortality rates regardless of whether revascularization is pursued. ESRD patients with CLI can be managed with: local wound care, endovascular or surgical revascularization, or amputation. Some patients may heal small foot wounds with local wound care alone, even if distal perfusion is marginal, as long as any infectious process has been controlled. Surgical revascularization has a mortality rate of 5-10% but has a high chance of limb salvage. However, overall 5-year survival may be as low as 28%. Endovascular therapy also carries a high perioperative mortality risk in this population with similar limb salvage rates. Amputation is indicated in patients with advanced stage CLI, as described by the Society for Vascular Surgery's Wound, Ischemia and foot Infection (WIfI) system. Statistical models predict that endovascular or surgical revascularization strategies are less costly and more functionally beneficial to patients than primary amputation alone. Decisions on how to manage ESRD patients with CLI are complex but revascularization can often result in limb salvage, despite limited overall survival. Dialysis patients with good life expectancy and good quality conduit may benefit most from surgical bypass.
Keywords: end-stage renal disease; endovascular therapy; lower extremity bypass; peripheral arterial disease.
Comment in
-
Commentary on Lower Extremity Revascularization in the Patient With End-Stage Renal Disease.Vasc Endovascular Surg. 2017 Feb;51(2):111. doi: 10.1177/1538574416674844. Vasc Endovascular Surg. 2017. PMID: 28209088 No abstract available.
Similar articles
-
Cost-effectiveness of revascularization for limb preservation in patients with end-stage renal disease.J Vasc Surg. 2014 Aug;60(2):369-374.e1. doi: 10.1016/j.jvs.2014.02.003. Epub 2014 Mar 20. J Vasc Surg. 2014. PMID: 24657067 Free PMC article.
-
Predictive ability of the Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system after first-time lower extremity revascularizations.J Vasc Surg. 2017 Mar;65(3):695-704. doi: 10.1016/j.jvs.2016.09.055. Epub 2017 Jan 7. J Vasc Surg. 2017. PMID: 28073665 Free PMC article.
-
Open Versus Endovascular Revascularization of Below-Knee Arteries in Patients With End-Stage Renal Disease and Critical Limb Ischemia.Vasc Endovascular Surg. 2018 Nov;52(8):613-620. doi: 10.1177/1538574418789036. Epub 2018 Jul 18. Vasc Endovascular Surg. 2018. PMID: 30021493
-
The Double Burden: Deciphering Chronic Limb-Threatening Ischemia in End-Stage Renal Disease.Ann Vasc Surg. 2024 Oct;107:105-121. doi: 10.1016/j.avsg.2023.12.102. Epub 2024 Apr 9. Ann Vasc Surg. 2024. PMID: 38599491 Review.
-
Lower extremity critical limb ischemia: A review of clinical features and management.Trends Cardiovasc Med. 2020 Apr;30(3):125-130. doi: 10.1016/j.tcm.2019.04.002. Epub 2019 Apr 15. Trends Cardiovasc Med. 2020. PMID: 31005554 Review.
Cited by
-
Prognostic Value of Hospital Frailty Risk Score and Clinical Outcomes in Critical Limb-Threatening Ischemia and End-Stage Kidney Disease.J Am Heart Assoc. 2024 Nov 5;13(21):e036963. doi: 10.1161/JAHA.124.036963. Epub 2024 Nov 4. J Am Heart Assoc. 2024. PMID: 39494596 Free PMC article.
-
Combination of melatonin-delivered endothelial progenitor cells with S-nitroso-N-acetyl-DL-penicillamine for improving critical limb ischemia in the rat.Am J Transl Res. 2024 Sep 15;16(9):5020-5037. doi: 10.62347/OCFT1003. eCollection 2024. Am J Transl Res. 2024. PMID: 39398551 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous